673P Cabozantinib-nivolumab (CN) vs. nivolumab-cabozantinib (NC) in patients (pts) with metastatic clear cell renal cell carcinoma (mRCC) following one prior VEGFR tyrosine kinase inhibitor (TKI): The CABIR multicentric matching-adjusted study

Autor:	S. Hans, I. Korakis, R. Elaidi, L. Phan, Raffaele Ratta, E. Braychenko, Ali Hasbini, Thomas Ryckewaert, Gwenaelle Gravis, S. Emambux, Philippe Barthélémy, N. Houede, M. Bennamoun, Yann-Alexandre Vano, Stéphane Oudard, S. Cournier, Denis Maillet, F. Schlürmann, Delphine Topart, Delphine Borchiellini
Rok vydání:	2021
Předmět:	Cabozantinib business.industry VEGFR tyrosine kinase inhibitor Hematology medicine.disease chemistry.chemical_compound Clear cell renal cell carcinoma Oncology chemistry Cancer research Medicine In patient Nivolumab business
Zdroj:	Annals of Oncology. 32:S696-S697
ISSN:	0923-7534
DOI:	10.1016/j.annonc.2021.08.069
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::dfc7863276c30cba5e13f99dca73d06c https://doi.org/10.1016/j.annonc.2021.08.069 Zobrazit plný text záznamu